News and Announcements
Cellmid Ltd – CEO Interview
- Published November 09, 2012 6:14PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Cellmid (ASX: CDY) develops innovative therapies and diagnostics for cancer, inflammation and heart attack. CDY has the largest global IP portfolio related to growth factor midkine (MK). Its most advanced program is for MK antibodies targeting cancer/inflammation. CDY is also developing MK protein to treat heart attack and other ischemia.
Executive Interviews
The $3.5 Trillion Succession Wave: Why 48% of Australian Business Owners Are About to Destroy Value
Australia’s Largest Wealth Transfer Has No Exit Plan Australian business succession planning is broken. An estimated $3.5 trillion in assets will pass from Baby Boomers to younger generations over the next two decades. The numbers reveal a crisis. 48% of Baby Boomer business owners plan to exit within five years. Only 24% have formal succession […]
The Great Life Science Reset: Why the “Sick Care” Model is Failing
The data reveals a significant transition: the end of the traditional sick care model and the rise of a proactive healthcare ecosystem. Learn how smart money is utilising AI to cut drug discovery times in half, transform diagnostics to detect complex diseases in days, and create efficiencies to scale the healthcare system without a proportional increase in costs.
Australia’s A$4 Trillion Generational Pivot
Australia’s wealth management landscape is undergoing a dramatic transformation. For decades, family offices operated quietly during the “Great Moderation”, an era characterised by low volatility, cheap capital, and global economic synchronisation. Today, that stability has given way to fiscal uncertainty, geopolitical tensions, and intensifying regulatory scrutiny. Yet amid this global turbulence, Australia has emerged as […]
Backed By Leading Investment Groups and Family Offices
